News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Edison Pharmaceuticals, Inc. Licenses Drug from Centocor, Inc. (JNJ) for Rare Diseases


1/5/2010 10:39:27 AM

MOUNTAIN VIEW, Calif., Jan. 5 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has licensed CNTO-530, a clinical-stage compound discovered and developed by Centocor R&D, Inc. for clinical evaluation in rare mitochondrial and other neglected diseases. The terms of the transaction have not been disclosed.

Edison Pharmaceuticals, Inc.



Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES